Abstract
Childhood-onset chronic inflammatory demyelinating polyneuropathy (CIDP) are generally responsive to conventional immunosuppressant treatments. However about 20% of patients may be refractory to several treatments and the disease has poor outcome. Rituximab is becoming a promising treatment in selected adult cases of severe CIDPs. We report the effectiveness of Rituximab in a refractory childhood-onset CIDP and we suggest this treatment as an effective choice in unresponsive childhood CIDP.
Original language | English |
---|---|
Pages (from-to) | 301-303 |
Number of pages | 3 |
Journal | European Journal of Paediatric Neurology |
Volume | 16 |
Issue number | 3 |
DOIs | |
Publication status | Published - May 2012 |
Keywords
- CIPD
- Polineuropathy
- Rituximab
ASJC Scopus subject areas
- Clinical Neurology
- Pediatrics, Perinatology, and Child Health